plug and bldp....... tell me how sun tan lotion companies have a better pps than these stocks.. i am starting to surrender.............. at least 20 years of waiting for tomorrow..........
Where is the pr. No way is it launched. Tv spots, business reports .. Not a thing about it.. What idiot would launch a product like this.. This is a medical game changer. There is no launch.. Al would have called first........
Afrezza Breathes Life Into MannKind
Comment Now Follow Comments
Any day now MannKind (NASDAQ:MNKD), is expected to launch its lead product Afrezza, an inhalable form of insulin. The company’s founder and namesake, Alfred Mann, has invested almost $1 billion of his own money to bring this product to market. Nate Pile’s best idea for 2015 is to invest alongside this successful serial entrepreneur as Afrezza brings MannKind to fruition.
Nate Pile is a Marketocracy Master and the Editor of Nate’s Notes which Mark Hulbert ranks #1 for the last 15 and 10 year periods, and #2 for the last 1, 3, and 5 year periods. Nate’s Marketocracy portfolio was up almost 34% last year, but perhaps more impressively, he has beaten both Warren Buffett and the top performing U.S. mutual fund manager for the last decade. Click here to review Nate’s track record.
Ken: Why is Afrezza better than insulins currently sold by market leaders Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY)?
Nate: To be sure, the advantage that gets talked about first – and usually with the most enthusiasm – is the fact that it is inhaled rather than injected, and while this will admittedly play a bigger role with newly diagnosed diabetics going forward, than it will with existing patients who are already used to injecting themselves several times a day, my own very small (and admittedly unscientific) survey suggests that a sizable portion of this patient population would also be more than happy to skip the injections, despite the fact that the needle sticks have become ‘tolerable’ as smaller and smaller needles have become available over the years.
In addition, a number of people I have spoken with have expressed excitement at the thought of being able to take their insulin during lunchtime meetings (or any other restaurant situation, for that matter) by simply taking a discrete puff on their inhaler, rather than leaving the table to give themselves an injection or playing the old “jab their leg under the table” game in order to spare others from watching the injection.
However, along with this “ease of use” feature, I believe an even more important piece of the puzzle is Afrezza’s pharmacokinetic (PK) profile, something we can talk about a little later in the interview.
Don't you know that the last people to control the pps are the share holders...Lets face it.. We all got taken in by Tobin , even fox news threw him off the air